Budigalimab clinical trials
Budigalimab is named as an intervention in 12 current clinical trials in our USA, Spain, Japan, France, Taiwan, Israel, China, Canada, Australia, South Korea, Italy, Germany, Belgium, Poland, UK, Turkey and Netherlands registers. 3 are recruiting patients now. The most common phase is Phase 1. The lead sponsor is AbbVie. The most-studied condition is Non-Small Cell Lung Cancer.
How Budigalimab works
All drug targets →- Programmed cell death protein 1 inhibitor InhibitorTarget: PDCD1 programmed cell death 1ChEMBL only
- Hepatocellular carcinomaPhase 2/3
- Non-small cell lung carcinomaPhase 2/3
- HIV infectious diseasePhase 2
- Esophageal adenocarcinomaPhase 2
- Gastric adenocarcinomaPhase 2
- Gastroesophageal junction adenocarcinomaPhase 2
- Pancreatic adenocarcinomaPhase 2
- Urothelial carcinomaPhase 2
- Colorectal cancerPhase 1
- Endometrial cancerPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4297858, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Budigalimab
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Budigalimab
12 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Budigalimab
17 conditionsAll 17 conditions
| Condition (as registered) | Trials |
|---|---|
| Non-Small Cell Lung Cancer | 2 |
| Advanced Solid Tumors Cancer | 2 |
| Advanced Solid Tumors | 2 |
| Hepatocellular Carcinoma | 2 |
| Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma | 1 |
| Gastroesophageal Junction Adenocarcinoma | 1 |
| Esophageal Adenocarcinoma | 1 |
| Non Small Cell Lung Carcinoma | 1 |
| c-MET | 1 |
| Advanced Squamous Tumors | 1 |
| Head and Neck Squamous Cell Carcinoma | 1 |
| Micro Satellite Stable Colorectal Cancer | 1 |
| Gastric/Esophageal Cancer | 1 |
| Urothelial Carcinoma | 1 |
| Cancer | 1 |
| Triple-Negative Breast Cancer (TNBC) | 1 |
| Non-small-cell-lung-cancer (NSCLC) | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| AbbVie | 12 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Budigalimab trials
How many clinical trials are testing Budigalimab?
12 current trials in our USA, Spain, Japan, France, Taiwan, Israel, China, Canada, Australia, South Korea, Italy, Germany, Belgium, Poland, UK, Turkey and Netherlands registers name Budigalimab (also registered as ABBV-181) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Budigalimab trials recruiting patients?
Yes. 3 of the 12 trials are recruiting: 3 with sites in USA, 1 with sites in Spain, 3 with sites in Japan, 1 with sites in France, 2 with sites in Taiwan, 2 with sites in Israel, 1 with sites in China, 2 with sites in Canada, 1 with sites in Australia, 1 with sites in South Korea, 1 with sites in Italy, 1 with sites in Germany, 1 with sites in Belgium, 1 with sites in Poland, 1 with sites in UK and 1 with sites in Turkey. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Budigalimab clinical trials?
The lead sponsor is AbbVie. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Budigalimab works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Budigalimab works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Budigalimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.